<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297128</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG R03 (96) / TAKO 06</org_study_id>
    <nct_id>NCT00297128</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiation With Capecitabine and Cetuximab</brief_title>
  <official_title>Preoperative Chemoradiation With Capecitabine and Cetuximab Within a Multidisciplinary Therapeutic Approach in Patients With Operable T3-T4 Rectal Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Gesellschaft mbH, Austria</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  feasibility and tolerance of preoperative therapy with Cetuximab in combination with
           Capecitabine and radiotherapy for patients with locally advanced operable rectal
           carcinoma

        -  collection of response rate (T-downstaging, pathological complete remission),
           correlation of responsiveness with EGFR-status
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma</measure>
    <time_frame>descriptive evaluation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status</measure>
    <time_frame>description evaluation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2 bid (on each therapy day of first 4 therapy weeks)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400mg/m2 week 1, 250mg/m2 week 2-4</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-80

          -  bioptical confirmed adenocarcinoma of the rectum in operable T3-T4NxM0 status. In
             spite of infiltration of the neighbouring organs the tumor has to be basically
             surgically complete resectable

          -  no former chemotherapy, radiotherapy of pelvis or abdomen and/or tumor resection of a
             rectum carcinoma

          -  WHO performance status 0-2

          -  adequate bone marrow reserve (granulocytes - not more than 1.500/µl; thrombocytes -
             not more than 100.000/µl)

          -  adequate hepatic function ( bilirubin - not more than 1.5 x ULN; GOT and GPT - not
             more than 3.5 x ULN)

          -  adequate renal function (creatinin - not more than 1.5 mg/dl)

          -  women of childbearing potential: exclusion of pregnancy (negative urin or serum
             pregnancy test)

          -  willingness of women of childbearing potential and accordingly of potent men to use
             approved contraceptives (e.g. birth-control pill, loop, condom) during and at least 3
             month after conclusion of the study

          -  life expectancy of at least 3 month

          -  signed Informed Consent before recruitment

          -  exclusion of distant metastases at the time of recruitment

        Exclusion Criteria:

          -  former radiotherapy of pelvis or abdomen

          -  former chemotherapy

          -  any other kind of malign tumor (except adequate treated skin basalioma or in situ
             cervical carcinoma) in the last 5 years

          -  general contraindication or known hypersensitivity against Cetuximab and/or
             Capecitabine

          -  Non malign disease, if there is a contraindication with radiotherapy or chemotherapy
             with Cetuximab and Capecitabine or a resection of the rectum: high-graded cardiac
             insufficiency, angina pectoris, hypertension or arrhythmia, hepatic disease,
             significant neurological or psychiatric disorders

          -  florid, serious infections at the time of recruitment

          -  legally limited contractual capability or evidence of neurological or psychiatric
             disease, if it will constrict the patients compliance in the opinion of the
             investigator

          -  evidence of lacking cooperation of the patient

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Thaler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joerg Tschmelitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander de Vries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital BHB St. Veit/Glan, Surgery</name>
      <address>
        <city>St. Veit a. d. Glan</city>
        <state>Carinthia</state>
        <zip>9330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wiener Neustadt, Surgery</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Leoben</name>
      <address>
        <city>Leoben</city>
        <state>Styria</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck, Surgery</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHS Linz, Radiooncology</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University Salzburg - Oncology</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Radiotherapy</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.abcsg.at/</url>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pilot study</keyword>
  <keyword>rectal</keyword>
  <keyword>cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>preoperative</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>capecitabine</keyword>
  <keyword>cetuximab</keyword>
  <keyword>operable</keyword>
  <keyword>T4</keyword>
  <keyword>ABCSG</keyword>
  <keyword>TAKO</keyword>
  <keyword>R03</keyword>
  <keyword>96</keyword>
  <keyword>06</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

